EQUIVIR
Live / Applied — Third extension granted (statement of use) (as of 14 Jan 2026)
What this means for you
Not registered yet, but its 23 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97280929
- Mark type
- Stylized text
- Filed
- 23 Feb 2022
- Published for opposition
- 10 May 2022
- Attorney of record
- Michael S. Hargis
Goods and services
- Class 005 — Pharmaceuticals: antivirals, excluding antivirals for the treatment and prevention of hepatitis B, HIV, or AIDS; pharmaceutical preparations, namely, antivirals, excluding antivirals for the treatment and prevention of hepatitis B, HIV, or AIDS
Owner
- Global Biolife, Inc., Houston, TX, US
- Global Biolife, Inc., Houston, TX, US
Prosecution history
- 26 Feb 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 26 Feb 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 15 Jan 2026 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 15 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jan 2026 — SOU EXTENSION 3 GRANTED
- 14 Jan 2026 — SOU EXTENSION 3 FILED
- 14 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 17 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jul 2025 — SOU EXTENSION 2 GRANTED
- 16 Jul 2025 — SOU EXTENSION 2 FILED
- 16 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jan 2025 — SOU EXTENSION 1 GRANTED
- 02 Jan 2025 — SOU EXTENSION 1 FILED
- 01 Jan 2025 — SOU TEAS EXTENSION RECEIVED